CJC-1295 NO DAC (5mg)
CJC-1295 NO DAC dosing protocols utilize this synthetic 29-amino acid GHRH analog (also known as Modified GRF 1–29 or Mod GRF) to stimulate natural, pulsatile growth hormone secretion from the pituitary gland. Unlike exogenous GH, it preserves the physiological feedback loop, supporting enhanced GH and IGF‑1 levels with natural hormonal rhythms. The literature describes 100 mcg per injection, 1–3 times daily, subcutaneously.
Reviewed by the AllPeptides.eu Editorial Team·Last reviewed: 2026-06-16
Educational information. Not medical advice, and no efficacy claim is implied. Regulatory approval is not a use recommendation by AllPeptides.eu.
⚠️ For informational/educational purposes only. Not medical advice. We do not sell any products. Self-treatment carries serious risks — consult a healthcare professional. Disclaimer
Research monograph
See the full CJC-1295 encyclopedia page with mechanism, evidence tier, related variants and research context.
How It Works
CJC-1295 NO DAC (Modified GRF 1–29) is a truncated GHRH analog with four amino acid substitutions (D‑Ala2, Gln8, Ala15, Leu27) that enhance stability against enzymatic degradation. It binds to GHRH receptors on pituitary somatotrophs, stimulating the synthesis and pulsatile release of endogenous growth hormone. Unlike exogenous GH administration, GHRH analogs preserve the physiological feedback loop. Its short half-life (~30 minutes) produces distinct GH pulses that mimic the natural secretion pattern.
Quick Start
- Reconstitution: Add 3.0 mL bacteriostatic water → ~1.67 mg/mL concentration.
- Typical range: 100 mcg per injection, 1–3× daily (100–300 mcg/day).
- Storage: Lyophilized: refrigerate 2–8 °C; after reconstitution, refrigerate; use within 1–2 weeks; for long-term storage freeze ≤−20 °C.
Typical / Gradual Approach (3 mL = ~1.67 mg/mL)
Route: Subcutaneous | Frequency: 1–3× daily
| Week | Dose | Units (per injection) |
|---|---|---|
| Weeks 1–2 | 100 mcg | 6 Units (0.06 mL) |
| Weeks 3–12 | 100 mcg | 6 Units (0.06 mL) |
Studies report subcutaneous administration of 100 mcg per injection, 1–3 times daily, with the first dose at bedtime to align with natural nocturnal GH pulsatility.
Related compounds
Reconstitution Steps
- Withdraw 3.0 mL of bacteriostatic water.
- Inject slowly down the side of the vial; avoid frothing.
- Gently swirl or rotate until dissolved.
- Label and refrigerate at 2–8 °C, protecting from light.
Protocol Overview
- Goal: Stimulate pulsatile GH release and increase IGF‑1 to support body composition, recovery, and metabolic health.
- Schedule: Daily subcutaneous injections for 8–12 weeks (extendable to 16).
- Storage: Lyophilized refrigerated/frozen; reconstituted refrigerated.
Dosing Protocol
- Initiation: 100 mcg 1×/day at bedtime (Wks 1–2).
- Target: 100 mcg 2–3×/day (Wks 3–12).
- Frequency: 1–3× daily (subcutaneously); the bedtime dose first.
- Cycle Duration: 8–12 weeks; optional extension to 16.
- Timing: Nightly to align with nocturnal GH pulses; rotate sites.
- Break between cycles: Post-cycle, a washout period of 4–6 weeks is recommended. Without DAC, the half-life is short (~30 minutes), but a pause prevents GHRH receptor desensitization.
Washout & Cycle Restart
When can I restart?
Post-cycle, a washout period of 4–6 weeks is recommended. Without DAC, the half-life is short (~30 minutes), but a pause prevents GHRH receptor desensitization.
Minimum wait period: 4 weeks
Storage Instructions
- Lyophilized: Refrigerate 2–8 °C; freeze ≤−20 °C for extended storage.
- Reconstituted: Refrigerate 2–8 °C; use within 1–2 weeks; avoid freeze-thaw cycles.
- Allow to reach room temperature before opening.
Important Notes
- Administer in a fasted state (≥2 hours) to optimize GH response.
Potential Benefits & Side Effects
Potential Benefits:
- Stimulates pulsatile GH release and increases IGF‑1 with chronic administration.
- May support improvements in body composition (increased lean mass, reduced fat).
- Potentially enhances recovery, sleep quality, and energy levels.
- Generally well-tolerated; mild injection site reactions, transient flushing, or headache.
Potential Side Effects:
- Flushing / sensation of warmth (common, transient).
- Headache (transient).
- Fluid retention / mild edema.
- Injection site reactions (redness, sensitivity).
- Numbness/tingling (rare, GH-related).
⚠️ Serious Warnings & Long-Term Risks
The following warnings are based on published literature, FDA labels, and post-marketing surveillance. They do not constitute medical advice. Consult a healthcare professional.
Theoretical risk (GH/IGF-1 elevation)
Without DAC, GH elevation is more physiological (pulsatile). Theoretical concern with long-term use.
📄 J Clin Endocrinol Metab 2006References
- Modified GRF (1–29): Structure, Substitutions, Pharmacokinetics — Wikipedia — Modified GRF (1–29): structure, substitutions, pharmacokinetics
View Source - Prolonged GH/IGF-I Stimulation by CJC-1295 — J Clin Endocrinol Metab (2006) — Prolonged GH/IGF-I stimulation by CJC-1295
View Source - CJC-1295 Normalizes Growth in GHRH KO Mice — Am J Physiol (2006) — CJC-1295 normalizes growth in GHRH KO mice
View Source - Sermorelin: Improved Management of Adult GH Deficiency (PMC) — Sermorelin: improved management of adult GH deficiency
View Source - Safety and Efficacy of GH Secretagogues — Review (PMC) — Safety and efficacy of growth hormone secretagogues
View Source
Recommended Supplements
L-Arginine + L-Ornithine
ZMA (Zinc + Magnesium + B6)
External Sources & Regulatory Status
Regulatory Approvals
Research-only — Modified GRF(1-29)
Educational information. Not medical advice, and no efficacy claim is implied. Regulatory approval is not a use recommendation by AllPeptides.eu.
Continue Your Research
Explore tools and guides related to this protocol.
Important Disclaimer
The content of this website is provided exclusively for informational and educational purposes within the context of research literature.
Read the full Disclaimer →